Bausch Health Companies Inc (BHC) - Total Liabilities
Based on the latest financial reports, Bausch Health Companies Inc (BHC) has total liabilities worth CA$25.58 Billion CAD (≈ $18.50 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bausch Health Companies Inc - Total Liabilities Trend (1993–2025)
This chart illustrates how Bausch Health Companies Inc's total liabilities have evolved over time, based on quarterly financial data. See BHC current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Bausch Health Companies Inc Competitors by Total Liabilities
The table below lists competitors of Bausch Health Companies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Farglory Land Development Co Ltd
TW:5522
|
Taiwan | NT$64.70 Billion |
|
Beijing Dabeinong Technology Group Co Ltd
SHE:002385
|
China | CN¥19.82 Billion |
|
CETC Digital Technology Co Ltd
SHG:600850
|
China | CN¥6.16 Billion |
|
Droneshield Ltd
AU:DRO
|
Australia | AU$38.99 Million |
|
China Yuchai International Limited
NYSE:CYD
|
USA | $14.75 Billion |
|
G2 Goldfields Inc.
TO:GTWO
|
Canada | CA$3.98 Million |
|
Shenzhen Forms Syntron Information Co Ltd
SHE:300468
|
China | CN¥132.65 Million |
|
S-1 Corp
KO:012750
|
Korea | ₩668.35 Billion |
Liability Composition Analysis (1993–2025)
This chart breaks down Bausch Health Companies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Bausch Health Companies Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -12.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bausch Health Companies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bausch Health Companies Inc (1993–2025)
The table below shows the annual total liabilities of Bausch Health Companies Inc from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$25.94 Billion ≈ $18.77 Billion |
-3.36% |
| 2024-12-31 | CA$26.84 Billion ≈ $19.42 Billion |
-2.14% |
| 2023-12-31 | CA$27.43 Billion ≈ $19.84 Billion |
+7.89% |
| 2022-12-31 | CA$25.43 Billion ≈ $18.39 Billion |
-13.03% |
| 2021-12-31 | CA$29.24 Billion ≈ $21.15 Billion |
-4.44% |
| 2020-12-31 | CA$30.59 Billion ≈ $22.13 Billion |
-6.52% |
| 2019-12-31 | CA$32.73 Billion ≈ $23.67 Billion |
+32.86% |
| 2018-12-31 | CA$24.63 Billion ≈ $17.82 Billion |
-21.93% |
| 2017-12-31 | CA$31.55 Billion ≈ $22.82 Billion |
-21.65% |
| 2016-12-31 | CA$40.27 Billion ≈ $29.13 Billion |
-6.20% |
| 2015-12-31 | CA$42.93 Billion ≈ $31.06 Billion |
+105.25% |
| 2014-12-31 | CA$20.92 Billion ≈ $15.13 Billion |
-8.00% |
| 2013-12-31 | CA$22.74 Billion ≈ $16.45 Billion |
+59.75% |
| 2012-12-31 | CA$14.23 Billion ≈ $10.30 Billion |
+55.81% |
| 2011-12-31 | CA$9.13 Billion ≈ $6.61 Billion |
+55.25% |
| 2010-12-31 | CA$5.88 Billion ≈ $4.26 Billion |
+725.63% |
| 2009-12-31 | CA$712.67 Million ≈ $515.54 Million |
+68.89% |
| 2008-12-31 | CA$421.97 Million ≈ $305.24 Million |
-12.87% |
| 2007-12-31 | CA$484.30 Million ≈ $350.33 Million |
-45.59% |
| 2006-12-31 | CA$890.14 Million ≈ $643.91 Million |
+10.09% |
| 2005-12-31 | CA$808.54 Million ≈ $584.89 Million |
+23.66% |
| 2004-12-31 | CA$653.86 Million ≈ $472.99 Million |
-37.20% |
| 2003-12-31 | CA$1.04 Billion ≈ $753.17 Million |
+5.37% |
| 2002-12-31 | CA$988.12 Million ≈ $714.79 Million |
+381.05% |
| 2001-12-31 | CA$205.41 Million ≈ $148.59 Million |
-76.38% |
| 2000-12-31 | CA$869.81 Million ≈ $629.21 Million |
+335.34% |
| 1999-12-31 | CA$199.80 Million ≈ $144.53 Million |
+34.36% |
| 1998-12-31 | CA$148.70 Million ≈ $107.57 Million |
+717.03% |
| 1997-12-31 | CA$18.20 Million ≈ $13.17 Million |
-16.13% |
| 1996-12-31 | CA$21.70 Million ≈ $15.70 Million |
-53.13% |
| 1995-12-31 | CA$46.30 Million ≈ $33.49 Million |
+158.66% |
| 1994-12-31 | CA$17.90 Million ≈ $12.95 Million |
-30.89% |
| 1993-12-31 | CA$25.90 Million ≈ $18.74 Million |
-- |
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmac… Read more